Rickettsia tsutsugamushi Transmitted by the bite of chiggers Source of infection: Rats Characterized by fever, eschar, rash, and lymphadenopathy

Antigenically distrpersive microorganism Common antigen with Proteus OX-K Low resistance Vector: Mite The life cycle: ovum, larva, pupa, nainad and imago Only its larva (chigger) feed on humans

Epidemiology Proliferate in warm, wet environments Both a vector and a reservoir Route of transmission: bite of chigger Susceptibility: universal Immunity: long-lasting

immunity against the homologous strains; Partial immunity against the other heterologous strains Epidemiology Other epidemiological features: Geographic distribution: Asian-pacific region Sporadic Seasonal distribution: rainy seasons between May and November

F/Characteristic manifestations Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Characteristic manifestations 2. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Characteristic manifestations 3. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Characteristic manifestations 4. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Characteristic manifestations 5. Fever: Fever is the most prominent symptom. Lasting 1 2 weeks. Remittent fever accompanied by chill, headache, malaise, prostration, poor appetite.

Clinical manifestations Signs of multiorgan damage: Meningoencephalitis: delirium, convulsion, coma, and neck stiffness. Interstitial pneumonitis: cough, chest pain, breathlessness.

Clinical manifestations Signs of multiorgan damage: myocarditis: gallop rhythm, poor quality heart sounds, systolic murmurs. hepatitis: jaundice, hemorrhage. Natural course: 2 3 weeks.

Clinical manifestations 6. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 7. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 8. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 9. Fever: Fever is the most prominent symptom. Lasting 1 2 weeks. Remittent fever accompanied by chill, headache, malaise, prostration, poor appetite.

Clinical manifestations 10. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 11. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 12. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 13. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 14. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 15. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 16. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 17. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 18. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 19. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 20. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 21. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 22. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 23. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 24. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 25. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 26. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 27. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 28. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 29. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 30. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 31. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 32. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 33. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 34. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 35. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 36. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 37. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 38. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 39. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 40. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 41. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 42. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 43. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 44. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 45. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 46. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 47. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 48. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 49. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 50. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 51. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 52. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 53. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 54. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 55. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 56. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 57. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 58. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 59. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 60. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 61. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 62. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 63. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 64. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 65. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 66. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 67. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 68. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 69. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 70. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 71. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 72. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 73. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 74. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 75. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 76. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 77. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 78. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 79. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 80. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 81. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 82. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 83. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 84. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 85. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 86. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 87. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 88. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 89. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 90. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 91. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 92. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 93. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 94. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 95. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 96. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 97. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 98. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 99. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 100. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 101. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 102. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 103. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 104. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 105. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 106. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 107. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 108. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 109. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 110. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 111. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 112. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 113. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 114. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 115. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 116. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 117. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 118. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 119. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 120. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 121. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 122. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 123. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 124. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 125. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 126. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 127. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 128. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 129. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 130. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 131. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 132. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 133. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 134. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 135. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 136. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 137. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 138. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 139. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 140. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 141. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 142. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 143. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 144. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 145. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 146. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 147. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 148. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 149. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 150. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 151. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 152. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 153. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 154. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 155. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 156. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 157. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 158. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 159. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 160. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 161. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 162. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 163. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 164. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 165. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 166. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 167. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 168. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 169. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 170. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 171. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 172. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 173. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 174. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 175. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 176. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 177. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 178. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 179. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 180. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 181. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 182. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 183. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 184. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 185. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 186. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 187. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 188. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 189. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 190. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days. Seen in 35 100 of patients.

Clinical manifestations 191. Splenomegaly and hepatomegaly Splenomegaly : 30 50 of patients. Hepatomegaly: 10 20 of patients.

Complications Pneumonia, myocarditis, DIC, hepatitis. \K\T

Clinical manifestations 192. Eschar and ulceration: Characteristic lesion, Seen in 36.9 98% of patients. Localized in the inguinal, genital, axillary, and other concealed areas.

Clinical manifestations 193. Lymphadenopathy: Enlarged markedly regional lymph nodes near the eschar. Generalized lymphadenopathy. Painful, movable, not purulent.

Clinical manifestations 194. Rash: Appears on the 4th to the 6th day. Beginning on the trunk, spread to the extremities. Maculopapular, congestive, no itching. Lasting 3 7 days.

D. Molecular biologic assays Nucleic acid hybridization and PCR. Great potential for sensitive and specific detection of nucleic acid. Being evaluated. Limitation of technique and facilities conditions. Differential Diagnosis Other rickettsial diseases, typhoid fever, leptospirosis, malaria, dengue, septicemia, influenza Prognosis Fatality rate: 9~60% without treatment. < 5% effective treatment. Treatment Chloramphenicol, tetracycline, doxycycline Chloramphenicol: 1.5~2g daily, divided into 3~4 aliquots. Fever abates within 48 hours. Total course: 10~14 days. Side effects: suppression of bone marrow and aplastic anemia. Prevention Eliminating the source of infection. Reducing and controlling the vectors. Individual protection: Avoiding contact with mites: the best method. Definition and introduction One of parasitic diseases. Caused by the infection with the tissue larvae of Taenia solium. Acquired by ingestion of Taenia solium eggs in contaminated foods. Humans: definite host and intermediate host. Definition and Introduction Human infected with Taenia solium in two forms: intestinal Taenia solium and cysticercosis. Cysticercosis has greater clinical significance. Cysticercosis: human tissue infection with the intermediate cyst forms of pork tapeworm. Cysticercus located in the subcutaneous tissue, muscle, brain. Etiology and Pathogenesis Taenia solium eggs passed out from patients. Eggs taken in by the fecal-oral route. Eggs digested by gastric juice to liberate oncosphere. Oncosphere penetrates the intestinal wall into blood circulation. Located in subcutaneous tissue, muscle, brain. Scolex appears and develops into cysticercus. Etiology and Pathogenesis Cysticercus: Bladder-like, fluid-filled cyst. Containing an invaginated scolex. Surrounded by fibrous capsule. Multiple, 0.5~2cm in size. Etiology and Pathogenesis Cysticercus: Location in subcutaneous tissue and skeletal muscle to produce minimal, if any, symptoms; Location in brain to have serious effects; Location in substantial to be able to occupy the space to produce the relevant sign; Location in ventricuil to produce cysticercus racemosus. Epidemiology Geographic distribution: Latin America, East Europe, southeast Asia, Africa. Source of infection: patient. Transmission: fecal-oral route. Susceptibility: universal. Clinical Manifestation Depend on 2 factors: The location and number of infecting cysts; The inflammation exists. Brain cysticercosis: found in 60~92% of the total cases. Subcutaneous nodule: found in 2/3 of the total cases. Clinical Manifestation Brain cysticercosis The incubation period: within 5 years. Cerebral cysticercosis Epilepsy: Caused by cysticerci located in the cortex near to the motorium. Always the first and the only symptom. Clinical Manifestation Neurosis: May be the only manifestation in patients with cryptogenic cysticercosis. Intracranial hypertension symptoms: vomiting, headache, visual disturbances. Clinical Manifestation Ventricular cysticercosis Caused by acute obstruction of CSF circulation. Manifest as the valve syndrome (Brun's syndrome) with intermittent positional severe headache, vomiting, shock. Clinical Manifestation Subarachnoid cysticercosis Chronic, intermittent meningitis. Clinical Manifestation Mixed form More serious neuropsychic symptoms. Clinical Manifestation Ocular cysticercosis Single eye involved. Eye pain, decreasing vision, retinal detachment. Clinical Manifestation Subcutaneous or muscle cysticercosis Clinical Manifestation Diagnosis Definitive diagnosis: biopsy of tissue cyst. Clinical diagnosis: History of residence in an endemic area; Clinical manifestation; Plain film, CT, MRI; Suggestive laboratory finding: detection of specific IgG in serum or CSF. Treatment Albendazole 1g daily, 2 aliquots, 10 days, repeat it 2 weeks later. Praziquantel 3g daily, 3 aliquots, 3 days. Notice when treatment: Patients should be hospitalized during the drug therapy. Epilepsy should be controlled at the same time. Increased intracranial pressure should be decreased. Prevention Avoid consuming undercooked pork and contaminated food. Careful personal hygiene. High level of community sanitation. Avoid contact with the infected pigs. Treatment Pathology Basic lesion: inflammation of the walls of the small blood vessels Pathologic findings: eschar, lymphadenopathy, rash, enlargement of spleen and liver Serious pathologic manifestations: myocarditis, meningoencephalitis, pneumonia, interstitial nephritis Clinical manifestations Signs of multiorgan damage: Meningoencephalitis: delirium, convulsion, coma, and neck stiffness. Interstitial pneumonia: cough, chest pain, breathlessness. Clinical manifestations Signs of multiorgan damage: Myocarditis: gallop rhythm, poor quality heart sounds, systolic murmurs. Hepatitis: jaundice, hemorrhage. Natural course: 2~3 weeks. Clinical manifestations Signs of multiorgan damage: Interstitial nephritis: Latin America, East Europe, southeast Asia, Africa. Source of infection: patient. Transmission: fecal-oral route. Susceptibility: universal. Clinical manifestations Signs of multiorgan damage: Myocarditis: gallop rhythm, poor quality heart sounds, systolic murmurs. Hepatitis: jaundice, hemorrhage. Natural course: 2~3 weeks. Clinical manifestations Signs of multiorgan damage: Interstitial nephritis: Latin America, East Europe, southeast Asia, Africa. Source of infection: patient. Transmission: fecal-oral route. Susceptibility: universal.